Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …

Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …

Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …

BACKGROUND This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …

Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …

Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naıve patients with advanced non–small-cell lung cancer (NSCLC) and …

In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …

Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …

EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line
treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR …